A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon - Full Text View

Sponsored by:	MediQuest Therapeutics
Information provided by:	MediQuest Therapeutics
ClinicalTrials.gov Identifier:	NCT00577304

Purpose

The purpose of this research study is to test the safety, tolerability, and effectiveness of Topical AmphiMatrix with Nitroglycerin (MQX0503) to relieve Raynaud's symptoms and increase blood flow to the fingers.

Condition	Intervention	Phase
Raynaud's Disease Raynaud's Disease Secondary to Scleroderma Raynaud's Disease Secondary to Other Autoimmune Disease	Drug: Nitroglycerin Drug: Topical AmphiMatrix	Phase III

MedlinePlus related topics: Autoimmune Diseases Raynaud's Disease

Drug Information available for: Nitroglycerin

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Crossover Assignment, Safety/Efficacy Study
Official Title:	A Study of a Topical Formulation of Nitroglycerin, MQX-503, and Matching Vehicle in the Treatment and Prevention of Raynaud's Phenomenon

Further study details as provided by MediQuest Therapeutics:

Primary Outcome Measures:

Reduction in Raynaud's Condition Score [ Time Frame: three months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Frequency and severity of adverse events. [ Time Frame: three months ] [ Designated as safety issue: Yes ]

Estimated Enrollment:	200
Study Start Date:	December 2007
Estimated Study Completion Date:	March 2008
Estimated Primary Completion Date:	March 2008 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
2 Placebo - Topical AmphiMatrix	Drug: Topical AmphiMatrix Individual pouch applicators containing 0.5 grams of Topical AmphiMatrix. Each dose is intended for topical usage on both hands up to five minutes before an anticipated Raynaud's attack or up to 5 minutes after the beginning of an actual Raynaud's attack. Limited to four applications per day; minimum of two hours between applications.
1: Active Comparator Topical AmphiMatrix with Nitroglycerin	Drug: Nitroglycerin Individual pouch applicators containing 0.5 grams of Topical AmphiMatrix with Nitroglycerin. Each dose contains 4.5mg of Nitroglycerin. Each dose is intended for topical usage on both hands up to five minutes before an anticipated Raynaud's attack or up to 5 minutes after the beginning of an actual Raynaud's attack. Limited to four applications per day; minimum of two hours between applications.

Arms

Assigned Interventions

2

Placebo - Topical AmphiMatrix

Drug: Topical AmphiMatrix

Individual pouch applicators containing 0.5 grams of Topical AmphiMatrix. Each dose is intended for topical usage on both hands up to five minutes before an anticipated Raynaud's attack or up to 5 minutes after the beginning of an actual Raynaud's attack. Limited to four applications per day; minimum of two hours between applications.

1: Active Comparator

Topical AmphiMatrix with Nitroglycerin

Drug: Nitroglycerin

Individual pouch applicators containing 0.5 grams of Topical AmphiMatrix with Nitroglycerin. Each dose contains 4.5mg of Nitroglycerin. Each dose is intended for topical usage on both hands up to five minutes before an anticipated Raynaud's attack or up to 5 minutes after the beginning of an actual Raynaud's attack. Limited to four applications per day; minimum of two hours between applications.

Detailed Description:

The purpose of this clinical study is to determine, in a controlled fashion, the ability of a topical formulation of Nitroglycerin, MQX-503, to improve the patient's health assessment as indicated by patient and physician assessments, decrease the frequency of Raynaud's events, decrease the duration of Raynaud's events, and decrease the symptoms (pain, tingling, numbness) in the fingers of Raynaud's patients. The study will include patients with moderate to severe primary Raynaud's Phenomenon (RP) and with moderate to severe Raynaud's Phenomenon secondary to autoimmune diseases, such as scleroderma.

Eligibility

Ages Eligible for Study:	15 Years to 70 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Outpatients ages 15 - 70.
Patients with a diagnosis of Raynaud's phenomenon.
Patients who agree to apply study medication to their fingers.
Patients who are willing to stop current topical vasodilator therapies.
Patients who agree not to start or change dosage of current oral vasodilator therapies.
Patients who agree not to use any nitrate therapy while participating in this study.
Negative pregnancy test in fertile women and agreement to use effective contraception throughout the study.

Exclusion Criteria:

Patients who currently use nitrate medication or medications known to interact with nitroglycerin.
Patients who have an allergy to nitroglycerin or common topical gel ingredients.
Patients with a history of severe headaches.
Patients with an unstable medical problem.
Patients with cognitive or language difficulties that would impair their ability to complete assessment of pain instruments.
Patients who have had a recent heart attack or other uncontrolled heart condition.
Patients who have participated in an investigational drug study within four weeks of visit one.
Patients who have clinically significant abnormal lab values.
Patients who have had recent major abdominal, thoracic or vascular surgery.
Patients with interfering skin conditions.
Pregnant or nursing women or women unwilling to comply with contraceptive requirements.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00577304

Locations

United States, California
Stanford University
Stanford, California, United States, 94305
United States, Colorado
University of Colorado Health Sciences Center
Denver, Colorado, United States, 80045
United States, Connecticut
University of Connecticut
Farmington, Connecticut, United States, 06030
United States, District of Columbia
Georgetown University
Washington, District of Columbia, United States, 20007
United States, Illinois
University of Chicago
Chicago, Illinois, United States, 60637
United States, Maryland
Johns Hopkins University
Baltimore, Maryland, United States, 21224
United States, Massachusetts
Boston University
Boston, Massachusetts, United States, 02118
United States, Michigan
Arthritis Education and Treatment Center, PLLC
Grand Rapids, Michigan, United States, 49546
United States, Minnesota
University of Minnesota
Minneapolis, Minnesota, United States, 55455
United States, New Jersey
University of Medicine and Dentistry of New Jersey
New Brunswick, New Jersey, United States, 08093
United States, New York
SUNY Stony Brook
Stony Brook, New York, United States, 11794
The Center for Rheumatology
Albany, New York, United States, 12206
United States, North Carolina
Carolina Arthritis
Wilmington, North Carolina, United States, 28401
United States, Ohio
University of Toledo
Toledo, Ohio, United States, 43614
United States, South Carolina
Medical University of South Carolina
Charleston, South Carolina, United States, 29425
United States, Texas
University of Texas at Houston
Houston, Texas, United States, 77030
United States, Wisconsin
Medical College of Wisconsin
Milwaukee, Wisconsin, United States, 53226

Sponsors and Collaborators

MediQuest Therapeutics

Investigators

Study Director:

Jan Ohrstrom, PhD

MediQuest Therapeutics

More Information

Sponsor web site This link exits the ClinicalTrials.gov site

Responsible Party:	MediQuest Therapeutics, Inc. ( Fred Dechow/President and CEO )
Study ID Numbers:	07-005
Study First Received:	December 18, 2007
Last Updated:	April 24, 2008
ClinicalTrials.gov Identifier:	NCT00577304
Health Authority:	United States: Food and Drug Administration

Keywords provided by MediQuest Therapeutics:

Raynaud's
Nitroglycerin
Scleroderma

Study placed in the following topic categories:

Nitroglycerin
Peripheral Vascular Diseases
Autoimmune Diseases

Raynaud Disease
Vascular Diseases
Neoplasm Metastasis

Additional relevant MeSH terms:

Vasodilator Agents
Neoplasms
Neoplastic Processes
Pathologic Processes
Immune System Diseases

Therapeutic Uses
Cardiovascular Diseases
Cardiovascular Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 16, 2009